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ABSTRACT
Purpose: Meningiomas are the commonest predominantly non-malignant brain tumour in adults. The use
of surgery appears to be increasing, and outcomes are thought to be good, but whole nation data for
England is scarce. The aim of this report is to examine the epidemiology of patients operated for cranial
and spinal meningioma in England, and to assess associations between outcomes and gender, age, men-
ingioma site (cranial or spinal), and grade.
Material and methods: A search strategy encompassing all patients coded with cranial and spinal men-
ingioma treated between January 1999 and December 2013 was obtained from data linkage between the
National Cancer Registration and Analysis Service and Hospital Episode Statistics for England.
Results: 25,694 patients were diagnosed with meningioma in England between 1999 and 2013, in whom
24,302 were cranial and 1392 spinal. Of these patients, 14,229 (60%) cranial and 1188 (85%) spinal men-
ingioma received surgery. Of those operated on 70.1% were women, and, where the tumour grade was
recorded, 79.5% were WHO grade I, 18.4% grade II, and 2.1% grade III. Five and ten year net survival rates
for surgically treated cranial meningiomas were respectively 90% and 81% for those with WHO grade I,
80% and 63% for grade II, and 30% and 15% for WHO grade III tumours. Overall survival after surgery is
better in women, younger adults, and people with spinal or lower grade meningiomas. Outcomes have
improved over the time period examined.
Conclusion: The outcome for patients with meningioma is good and is improving. However, there
remains a significant mortality related to the disease process.
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Meningiomas are a group of mostly non-malignant, slow-grow-
ing tumours of the central nervous system that are thought to be
derived from the meningothelial cells of the arachnoid layer
(Figure 1).1 They account for 37% of brain tumours overall and
39% of spinal tumours, have a reported cranial incidence of 8.3/
100,000 in the United States (US), are more common in older
people, in people of Afro-Caribbean ethnicity, and in women
(2.2 to 1).2 They are increasingly found incidentally, with only
43% diagnosed from histological confirmation in the US, and are
mostly World Heath Organization (WHO) grade I (80.6%), with
fewer being of higher grades (Grade II 17.4%, and grade III
2.1%).2 Common clinical symptoms include headache, progres-
sive neurological deficit, and seizures. Management options
include active monitoring, symptom control, surgical excision,
external beam radiotherapy (EBRT), and stereotactic radiosurgery
(SRS).3 Maximal surgical excision remains the mainstay of treat-
ment for all grades of cranial and spinal meningioma, but cranial
SRS and EBRT are increasingly used.3,4
There is little multicentre United Kingdom data published on
outcome after surgery for meningiomas. In 2013 English cancer
registry data were centralized allowing ready exploration of
national data on patients with brain tumours across the whole of
England (56.1 million people in 2011, Office for National
Statistics). The data are linked to information on hospital admis-
sions (Hospital episode statistics: HES), which include treatment
related to surgery, and pathology and radiology reports. In
addition, multidisciplinary team meetings (MDTs; or tumour
boards) feed diagnostic and therapy data directly to the National
Cancer Registration and Analysis Service (NCRAS). This makes
England unique in having detailed whole nation incidence and
treatment data for all patients diagnosed with a brain tumour.
The aim of this study was to examine the epidemiology of
patients having surgery for meningiomas, and the long-term out-
come related to the age and sex of the patient, the site (cranial or
spinal), and grade, over a 15 year period for the whole
of England.
Methods
A retrospective population based search examined data from
NCRAS, linked to Hospital Episode Statistics (HES), between 1st
January 1999 and 31st December 2013 (a 15-year period).
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International Classification of Diseases (ICD) 10 O2 site codes
used were C70, D32, and D42, ICD10 morphologies 9530–9539
and some M8000 in clinical/imaging diagnoses, and ICD10 O2
behaviours 0, 1, and 3 for WHO grades I (benign), II (atypical),
and III (malignant) respectively. Vital status was checked using
the NHS Personal Demographics Service (PDS) (http://systems.
hscic.gov.uk/demographics/pds/).
Net survival percentages were calculated using the STRS
(www.pauldickman.com/rsmodel/stata_colon/) commands respect-
ively in Stata version 13.1 SE (http://www.stata.com). Net survival
is the survival that would be observed if the only possible under-
lying cause of death was the disease under study.5 Net survival
was used as an adjunct to absolute survival, as patients with
meningiomas can live for extended periods, and net survival takes
into account expected mortality among patients of similar age
and gender. Net survival therefore allows an assessment of the
additional morbidity associated with the disease process.
Results
In England, between 1st Jan 1999 and 31st December 2013,
25,694 patients (71.1% female) were diagnosed with meningioma,
of which 24,302 were cranial and 1390 were spinal (Table 1).
Within this group, 15,417 (70.1% female) had surgery, 14,229
were cranial and 1188 were spinal. Meningioma numbers
increased with increasing age, with a mean age at treatment of
57.5 years (standard deviation 14.4, range 0 – 98 years). This
compared to a mean age of 73.9 of those who didn’t have surgery
(range 0 – 104). Three times more women than men had sur-
gery. 79.5% of tumours were WHO grade I, 18.4% grade II, and
2.1% grade III.
Five and ten year net survival for cranial meningiomas were
respectively 90% and 81% for WHO grade I, 80% and 63% for
grade II, and 30% and 15% for WHO grade III tumours (Table 2
and Figure 2). There was a significant reduction in 5 year net
survival over the age of 69 years, to less than 83% in men and
87% in women (Figure 3). This means that 27% of men age 70
to 79 years who had surgery for a cranial Meningioma died
within 5 years over and above what would be expected for their
age, and hence may be attributable to their meningioma, treat-
ment, or complications thereof. Patients with spinal meningiomas
did better in all grades, gender and ages (Table 2, Figure 2).
Women had better outcomes than men at all ages, both cranial
and spinal locations, and grades.
Figure 1. Meningioma clinical variety. A. Patient presented with a seizure and left hemiparesis, and had a WHO grade II meningioma excised uneventfully. B. Patient
presented with visual deterioration, and had 2 surgeries, and radiotherapy over a 20 year period for a WHO grade I meningioma. Vision deteriorated further and the
meningioma continued to grow. C. Patient with NF2 and multiple meningiomas presented de novo with headache at 52 yrs old. D. Patient presented with progressive
weakness (Figure 1D courtesy of Dr S Mills, The Walton Centre, Liverpool).
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Surgical outcomes improved over the 15-year period (Figure
4). For both cranial and spinal meningiomas, in both genders,
and at all ages and grades of tumour at both 1 and 3 years there
was an improvement in net survival.
Discussion
More than 2000 patients are diagnosed with meningioma each
year in England, with more than half receiving cranial or spinal
surgery. Numbers have been increasing year-on-year, with 52%
more diagnoses and 58% more resections in 2013 than 1999. Five
and ten year survival rates post-surgery are high, and are increas-
ing over time.
Meningiomas are the commonest primary cranial tumour type
in adults, and are unsurprisingly the commonest cranial tumour
operation.2,6 Incidence data published suggest 5.3 per 100,000
person years in the UK (7.19 for women, 3.05 for men), and an
age adjusted rate of 8.14/100,000 in the US, but those may both
be underestimates as rates of up to 2.3% at post-mortem have
been suggested.2,7 Meningiomas are known to be more common
with greater body adipose mass, which may relate to hormone
responsiveness.2,8,9 Growing obesity levels, as well as an ever
increasing elderly population and the availability and use of brain
imaging imply this number will continue to grow over time.
An examination of the demographic features shows consist-
ency with previous reports in other nations.2 A female prepon-
derance is present for both cranial and spinal meningiomas
(71.1% occur in women overall), which is consistent throughout
the literature.2 Meningiomas are more common with advancing
age, and the peak operative age band was 60–69 years. The def-
inition of meningioma grade has altered over the study period
with three iterations of the WHO Classification of Tumours of
the Nervous System.1,10,11 These alterations have refined the
diagnostic criteria for grade II meningiomas including brain
invasion in the 2007 classification, which has led to a reported
increase in incidence over the last 15 years, so the total figures
provided in the current study should overestimate slightly the
true incidence of grade I tumours, and underestimate that
for grade II if histological examination were to repeated using
the 2016 WHO classification.12 The rates of grade I, II, and III
tumours presented are however so similar to that from recent
US reports (80.4% vs 79.5% for grade I, 17.4% vs 18.4% for
grade II, and both at 2.1%) that it appears this change has not
made a significant difference. This might be due to the US fig-
ures not incorporating the newer histological grading scheme,
that some pathologists may have used brain invasion as a criteria
for upgrading an otherwise grade I meningioma before 2007,
that the US and UK are truly different populations, or more
likely that the effect of the histological changes may not be as
great as previously thought.
There is a substantial mortality associated with meningioma
surgery that is related to increasing adult age, higher grade, sub-
total resection, and being male.13–16 In patients with grade I
tumours, 19% of people are dead at 10 years over what one
would expect without the disease, and 37% of patients with grade
II tumours. This is a substantial reduction in survival for a
‘benign’ condition. For patients, their quality of life after surgery
is also important. Two large studies of 1722 and 291 patients
showed significant reductions in physical, cognitive, emotional,
and social function, and patients suffered significant fatigue and
sleep impairment following meningioma surgery.17,18
Cranial meningiomas can be broadly divided into skull base
tumours and non-skull base. The Surgical morbidity and mor-
tality described, might at first be thought to be related to a pre-
ponderance of skull base tumours. It was not possible in this
study to differentiate between skull base and non-skull base
meningiomas. Skull base meningioma are less common, have a
higher recurrence rate and worse progression free survival, but
are more likely to be grade I, have a slower growth rate, and
reports suggest a comparable net survival rate.16,19,20
Overall survival outcomes for surgically treated patients are
getting better. This improving trend, in light of greater subspeci-
alisation within surgical practice in the UK, may be used to fur-
ther support the role of the specialty tumour surgeon.6
Patients with surgically treated spinal meningiomas were even
more likely to be female than those treated with cranial disease
(3.5:1 vs 2.3:1). Differences in hormone responsiveness and gen-
omic makeup have been suggested to explain this difference.9,21
Treatment for symptomatic spinal meningiomas is surgery and
gross macroscopic resection with or without dural excision, with
or without radiotherapy or SRS for residual or recurrent disease,





All meningioma 25694 15,417
Subsite % of total
Cerebral meninges 24302 14,229 92.3
Spinal meninges 1392 1,188 7.7
Grade % of graded
GI 6887 6,422 79.5
GII 1586 1,489 18.4
GIII 186 169 2.1
GX 17035 7,337
Grade, diagnoses in 1999–2005 % of graded
GI 1248 1,105 80.8
GII 250 222 16.2
GIII 48 40 2.9
GX 8513 4,688
Grade, diagnoses in 2006–2013 % of graded
GI 5639 5,317 79.2
GII 1336 1,267 18.9
GIII 138 129 1.9
GX 8522 2,649
Gender % of total
Men 7412 4,615 29.9
Women 18282 10,802 70.1
Age group % of total
0–15 (child) 94 68 0.4
16–24 (TYA) 213 172 1.1
25–39 1871 1,559 10.1
40–49 3251 2,652 17.2
50–59 4500 3,627 23.5
60–69 5211 3,907 25.3
70–79 5157 2,760 17.9
80þ 5397 672 4.4
Diagnosis year % of total
1999 1315 779 5.1
2000 1370 812 5.3
2001 1343 790 5.1
2002 1447 851 5.5
2003 1462 865 5.6
2004 1536 953 6.2
2005 1586 1,005 6.5
2006 1628 1,024 6.6
2007 1821 1,146 7.4
2008 1942 1,215 7.9
2009 2019 1,209 7.8
2010 1997 1,150 7.5
2011 2067 1,171 7.6
2012 2151 1,214 7.9
2013 2010 1,233 8.0
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Table 2. Outcome for patients with meningioma in England treated with surgery 1999–2013.
Years after surgery
Alive at start of interval Died during interval
Kaplan-Meier crude survival Pohar-Perme net survival
N N Estimate (95% CI) Estimate (95% CI)
Cerebral meninges
All patients 1 13235 986 0.93 (0.93, 0.93) 0.94 (0.94, 0.95)
3 10633 538 0.89 (0.88, 0.89) 0.92 (0.91, 0.93)
5 8283 462 0.85 (0.84, 0.85) 0.90 (0.89, 0.91)
10 3359 719 0.74 (0.74, 0.75) 0.85 (0.84, 0.86)
Grade
GI 1 5554 268 0.95 (0.95, 0.96) 0.96 (0.96, 0.97)
3 4104 128 0.93 (0.92, 0.94) 0.96 (0.95, 0.96)
5 2898 117 0.90 (0.89, 0.91) 0.95 (0.94, 0.96)
10 453 157 0.81 (0.79, 0.83) 0.93 (0.90, 0.94)
GII 1 1354 94 0.94 (0.92, 0.95) 0.95 (0.93, 0.96)
3 925 82 0.87 (0.85, 0.89) 0.90 (0.88, 0.92)
5 580 60 0.80 (0.78, 0.82) 0.86 (0.83, 0.88)
10 99 71 0.63 (0.58, 0.67) 0.75 (0.70, 0.80)
GIII 1 116 47 0.71 (0.63, 0.77) 0.72 (0.64, 0.78)
3 64 37 0.47 (0.39, 0.54) 0.49 (0.40, 0.56)
5 26 19 0.30 (0.22, 0.38) 0.32 (0.24, 0.41)
10 5 8 0.15 (0.07, 0.26) 0.22 (0.13, 0.32)
GX 1 6214 577 0.92 (0.91, 0.92) 0.93 (0.92, 0.93)
3 5545 291 0.87 (0.86, 0.88) 0.90 (0.89, 0.91)
5 4782 266 0.83 (0.82, 0.84) 0.88 (0.87, 0.89)
10 2804 483 0.73 (0.72, 0.74) 0.82 (0.81, 0.84)
Gender
Men 1 3953 402 0.91 (0.90, 0.92) 0.92 (0.91, 0.93)
3 3110 257 0.84 (0.83, 0.85) 0.89 (0.87, 0.90)
5 2368 192 0.79 (0.77, 0.80) 0.86 (0.84, 0.87)
10 919 290 0.65 (0.63, 0.67) 0.78 (0.76, 0.81)
Women 1 9283 584 0.94 (0.94, 0.95) 0.95 (0.94, 0.95)
3 7526 281 0.91 (0.90, 0.92) 0.94 (0.93, 0.94)
5 5915 270 0.87 (0.87, 0.88) 0.92 (0.91, 0.92)
10 2440 429 0.79 (0.78, 0.80) 0.88 (0.86, 0.89)
Age group
0–39 1 1666 36 0.98 (0.97, 0.98) 0.98 (0.97, 0.99)
3 1401 19 0.97 (0.96, 0.97) 0.97 (0.96, 0.98)
5 1170 19 0.95 (0.94, 0.96) 0.96 (0.94, 0.97)
10 535 25 0.92 (0.91, 0.94) 0.93 (0.92, 0.95)
40–49 1 2499 42 0.98 (0.98, 0.99) 0.99 (0.98, 0.99)
3 2075 39 0.97 (0.96, 0.97) 0.97 (0.96, 0.98)
5 1656 36 0.95 (0.94, 0.96) 0.96 (0.95, 0.97)
10 709 38 0.92 (0.90, 0.93) 0.94 (0.93, 0.95)
50–59 1 3282 124 0.96 (0.96, 0.97) 0.97 (0.96, 0.97)
3 2709 78 0.94 (0.93, 0.95) 0.95 (0.94, 0.96)
5 2179 70 0.91 (0.90, 0.92) 0.93 (0.92, 0.94)
10 967 129 0.84 (0.82, 0.85) 0.89 (0.87, 0.90)
60–69 1 3341 257 0.93 (0.92, 0.94) 0.94 (0.93, 0.95)
3 2634 138 0.89 (0.88, 0.90) 0.92 (0.90, 0.93)
5 2018 117 0.84 (0.83, 0.86) 0.90 (0.88, 0.91)
10 760 199 0.72 (0.70, 0.74) 0.84 (0.82, 0.86)
70–79 1 2068 382 0.84 (0.83, 0.86) 0.87 (0.85, 0.88)
3 1551 206 0.75 (0.74, 0.77) 0.83 (0.81, 0.85)
5 1100 174 0.66 (0.64, 0.68) 0.78 (0.76, 0.81)
10 365 261 0.45 (0.42, 0.47) 0.69 (0.65, 0.72)
80þ 1 384 145 0.73 (0.69, 0.76) 0.78 (0.74, 0.82)
3 268 58 0.61 (0.56, 0.65) 0.77 (0.71, 0.82)
5 166 46 0.49 (0.44, 0.53) 0.76 (0.68, 0.82)
10 28 67 0.20 (0.15, 0.25) 0.64 (0.49, 0.76)
Spinal meningiomas
All patients 1 1143 45 0.96 (0.95, 0.97) 0.98 (0.97, 0.99)
3 877 50 0.91 (0.90, 0.93) 0.98 (0.95, 0.99)
5 693 34 0.88 (0.85, 0.90) 0.98 (0.93, 1.00)
10 263 64 0.76 (0.72, 0.79)
Grade
GI 1 576 20 0.97 (0.95, 0.98) 0.99 (0.96, 1.00)
3 388 21 0.92 (0.90, 0.94) 0.99 (0.92, 1.00)
5 284 14 0.89 (0.85, 0.91)
10 38 16 0.79 (0.73, 0.84)
GII, GIII, GX 1 568 25 0.96 (0.94, 0.97) 0.98 (0.95, 0.99)
3 491 29 0.91 (0.88, 0.93) 0.97 (0.93, 0.98)
5 410 20 0.87 (0.84, 0.89) 0.98 (0.91, 0.99)
10 226 48 0.74 (0.70, 0.78) 0.95 (0.81, 0.99)
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or higher grade tumours.22–24 Recurrences can occur years or
decades later and in a representative case series of 62 patients,
subtotal resection (Simpson grade III/IV) was associated with a
30% recurrence rate at a mean of 12 years later.25 There is a 98%
5 year net survival, but it appears quality of life may be affected.
A series of 13,792 admissions in the US for spinal meningiomas
showed that 42% were discharged to facilities other than home
or self-care suggesting an early associated morbidity.26
Molecular markers of meningiomas are becoming increasingly
important in clinical practice. Meningiomas are most commonly
associated with monosomy of chromosome 22, but are also asso-
ciated with deletion of Chromosome 1p, losses of chromosomes
6q, 9p, 10, 14q, and 18q in higher-grade tumours, as well as
mutations in the NF2 gene in both patients with neurofibroma-
tosis, and sporadic, meningiomas.9,27–30 Most meningiomas are
monoclonal tumours, and sporadic, but a few are associated with
tumour predisposition syndromes including neurofibromatosis
type 2, multiple endocrine neoplasia, and some DNA repair gene
abnormalities.31,32 Progesterone receptor expression is inversely
associated with meningioma grade.1 DNA methylation has been
used to better predict disease progression and may be important
in the future for predicting outcome, and further molecular
marker studies are ongoing.33,34 Molecular markers were not
available for the meningiomas in this study. Future epidemio-
logical studies incorporating molecular subtypes will help
improve our understanding of the associated clinical significance.
The Public Health England National Cancer Registration and
Analysis Service is a partnership operated by Public Health
England and amongst its aims is to promote efficient and effect-
ive data collection for tumour patients and to provide a common
national database for cancer datasets. It has now become manda-
tory for all trusts to collate data on patients with brain tumours
Table 2. Continued.
Years after surgery
Alive at start of interval Died during interval
Kaplan-Meier crude survival Pohar-Perme net survival
N N Estimate (95% CI) Estimate (95% CI)
Gender
Men 1 246 15 0.94 (0.91, 0.96) 0.96 (0.92, 0.98)
3 186 15 0.88 (0.83, 0.91) 0.94 (0.87, 0.97)
5 147 7 0.84 (0.79, 0.88) 0.96 (0.84, 0.99)
10 58 14 0.72 (0.63, 0.78)
Women 1 898 30 0.97 (0.95, 0.98) 0.99 (0.97, 0.99)
3 693 35 0.93 (0.91, 0.94) 0.99 (0.95, 1.00)
5 547 27 0.89 (0.86, 0.91) 0.99 (0.81, 1.00)
10 206 50 0.77 (0.73, 0.80)
Age group
0–59 1 424 5 0.99 (0.97, 1.00) 0.99 (0.97, 1.00)
3 335 4 0.98 (0.96, 0.99) 0.99 (0.96, 1.00)
5 276 5 0.96 (0.94, 0.98) 0.98 (0.95, 0.99)
10 122 5 0.94 (0.90, 0.96) 0.97 (0.92, 0.99)
60þ 1 720 40 0.95 (0.93, 0.96) 0.98 (0.95, 0.99)
3 543 46 0.88 (0.85, 0.90) 0.97 (0.93, 0.99)
5 418 29 0.83 (0.80, 0.86) 0.99 (0.75, 1.00)
10 142 59 0.66 (0.61, 0.70)
Figure 2. Long term outcomes. Kaplan Meier estimates of overall survival by grade and site of patients with histologically confirmed (operated) meningiomas in
England 1999–2013. G1: WHO grade I, G2: WHO grade II, G3: WHO grade III, GX: WHO grade unrecorded.
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and forward them to a national repository. This central data
repository allows whole country data for England to be analyzed
to gain an insight into different patient tumour groups and hope-
fully improve services across the country.
Limitations of the current study include the absence of com-
plete data on meningioma site (skull base vs non-skull base),
radiotherapy use and dose, SRS use, comorbidities, complications,
and further surgical episodes and treatment at recurrence. A
number of patients did not have meningioma grade documented,
but outcomes for that group suggest they were in similar propor-
tions to those recorded. Not all patients with incidental untreated
meningiomas will be coded and included in the NCRAS data-
base, and this is supported by the difference in incidence rates
between the US and UK populations.2,7 The recent inclusion of
radiology reports in the national data registry should help
address that issue. Net survival rates assume that patients with
meningiomas are similar to age and sex matched controls.
Patients with meningiomas are associated with greater body adi-
pose mass, and greater adipose mass may be associated with
other comorbidities including diabetes and vascular diseases,
which have implications for survival. Therefore the net figures
presented may overestimate slightly the effects of a diagnosis of
meningioma on survival.
Conclusions
The outcome for patients with meningioma is good, is improv-
ing, is better for women, and for younger patients and those
Figure 3. Influence of age. Net survival at 1 and 5 years for patients with WHO grade I cranial meningiomas diagnosed histologically (operated) 1999–2013 by age
and sex.
Figure 4. Variance in outcomes over time. Net survival for 1 and 5 year survivals by year of diagnosis for patients with histologically confirmed (operated) cranial
Meningioma broken down by year of diagnosis.
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with spinal meningiomas. Despite this, there remains a signifi-
cant mortality and morbidity related to this disease.
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